Abstract
Agonists and positive allosteric modulators of the α7 nicotinic acetylcholine receptor (nAChR) are currently being developed for the treatment of cognitive disturbances in patients with schizophrenia or Alzheimers disease. This review describes the neurobiological properties of the α7 nAChR and the cognitive effects of α7 nAChR activation, focusing on the translational aspects in the development of these drugs. The functional properties and anatomical localization of the α7 nAChR makes it well suited to modulate cognitive function. Accordingly, systemic administration of α7 nAChR agonists improves learning, memory, and attentional function in variety of animal models, and procognitive effects of α7 nAChR agonists have recently been demonstrated in patients with schizophrenia or Alzheimers disease. The α7 nAChR desensitizes rapidly in vitro, and this has been a major concern in the development of α7 nAChR agonists as putative drugs. Our review of the existing literature shows that development of tolerance to the behavioral effects of α7 nAChR agonists does not occur in animal models or humans. However, the long-term memory-enhancing effects seen in animal models are not mimicked in healthy humans and schizophrenic patients, where attentional improvement predominates. This discrepancy may result from inherent differences in testing methods or from species differences in the level of expression of α7 nAChRs in limbic brain regions, and may hamper preclinical evaluation of α7 nAChR activation. It is therefore important to consider the translational power of the animal models used before entering into a clinical evaluation of the pro-cognitive effects of α7 nAChR activation.
Keywords: Nicotine, Alzheimer's disease, schizophrenia, attention, working memory, prefrontal cortex, hippocampus, acetylcholine
Current Pharmaceutical Design
Title: Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
Volume: 16 Issue: 3
Author(s): Morten S. Thomsen, Henrik H. Hansen, Mikkelsen B. Timmerman and Jens D. Mikkelsen
Affiliation:
Keywords: Nicotine, Alzheimer's disease, schizophrenia, attention, working memory, prefrontal cortex, hippocampus, acetylcholine
Abstract: Agonists and positive allosteric modulators of the α7 nicotinic acetylcholine receptor (nAChR) are currently being developed for the treatment of cognitive disturbances in patients with schizophrenia or Alzheimers disease. This review describes the neurobiological properties of the α7 nAChR and the cognitive effects of α7 nAChR activation, focusing on the translational aspects in the development of these drugs. The functional properties and anatomical localization of the α7 nAChR makes it well suited to modulate cognitive function. Accordingly, systemic administration of α7 nAChR agonists improves learning, memory, and attentional function in variety of animal models, and procognitive effects of α7 nAChR agonists have recently been demonstrated in patients with schizophrenia or Alzheimers disease. The α7 nAChR desensitizes rapidly in vitro, and this has been a major concern in the development of α7 nAChR agonists as putative drugs. Our review of the existing literature shows that development of tolerance to the behavioral effects of α7 nAChR agonists does not occur in animal models or humans. However, the long-term memory-enhancing effects seen in animal models are not mimicked in healthy humans and schizophrenic patients, where attentional improvement predominates. This discrepancy may result from inherent differences in testing methods or from species differences in the level of expression of α7 nAChRs in limbic brain regions, and may hamper preclinical evaluation of α7 nAChR activation. It is therefore important to consider the translational power of the animal models used before entering into a clinical evaluation of the pro-cognitive effects of α7 nAChR activation.
Export Options
About this article
Cite this article as:
Thomsen S. Morten, Hansen H. Henrik, Timmerman B. Mikkelsen and Mikkelsen D. Jens, Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology, Current Pharmaceutical Design 2010; 16 (3) . https://dx.doi.org/10.2174/138161210790170094
DOI https://dx.doi.org/10.2174/138161210790170094 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
EPO and EPO-Receptor System as Potential Actionable Mechanism for the Protection of Brain and Heart in Refractory Epilepsy and SUDEP
Current Pharmaceutical Design Toxins Targeting Voltage-Activated Ca<sup>2+</sup> Channels and their Potential Biomedical Applications
Current Topics in Medicinal Chemistry Disrupted Functional Connectivity Related to Differential Degeneration of the Cingulum Bundle in Mild Cognitive Impairment Patients
Current Alzheimer Research Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Current Drug Targets Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery The Interaction of DNA-Binding Ligands with Trinucleotide-Repeat DNA: Implications for Therapy and Diagnosis of Neurological Disorders
Current Topics in Medicinal Chemistry Application of MicroPET in Basic Epilepsy Research
Current Medical Imaging Interferon-γ-Induced Neurotoxicity of Human Astrocytes
CNS & Neurological Disorders - Drug Targets Regulators of Platelet cAMP Levels: Clinical and Therapeutic Implications
Current Medicinal Chemistry Global Expression Studies of Schizophrenic Brain: A Meta-Analysis Study Linking Neurological Immune System with Psychological Disorders
CNS & Neurological Disorders - Drug Targets Amyloid β Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner
Current Alzheimer Research α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets Synaptic Potentiation and Sleep Need: Clues from Molecular and Electrophysiological Studies
Current Topics in Medicinal Chemistry CNS Transporters and Drug Delivery in Epilepsy
Current Pharmaceutical Design From Blood-to-Brain: Regulating the Permeability of the Blood-Brain Barrier
Current Psychopharmacology Recent Advances in Antiepileptic Herbal Medicine
Current Neuropharmacology Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Pyrrolizidine Alkaloids and their Biological Properties from Indian Heliotropium Species
Current Bioactive Compounds Patent Selections:
Recent Patents and Topics on Imaging (Discontinued)